摘要:
A curing agent for epoxy resin which comprises at least one selected from the compound of the formula (1) and its salt, as an effective component wherein X is —(CH2)n- or —(CH2)1-Y—(CH2)m- , Y is —N(R1)—, —O— or —S—, R1 is alkyl having 1 to 8 carbon atoms or amino. n is a number of 2, 3, 5 to 11, 1 and m are each a number of 1 to 8.
摘要:
The present invention provides an aqueous solution of an epoxy resin and a solid thereof, which is obtained by the following manner that an epoxy compound or a solution of the epoxy compound in organic solvent, and an amine compound of the formula (1), an aqueous solution thereof, a solution of the amine compound in organic solvent, or a solution thereof in a mixture of water and organic solvent, are mixed together so that the epoxy compound and the amine compound are reacted or polymerized to obtain a solution of an epoxy resin, to which water is added and heated to remove the organic solvent and unreacted amine compound, and a process for preparing the same NH2N(R1)(R2) (1) wherein R1 and R2 are the same or different and each is alkyl having 1 to 6 carbon atoms, alkylene having 2 to 11 carbon atoms or a group represented by —R3—N(R4)—R5— which are formed when both are bonded, R3 and R5 are the same or different and each is alkylene having 1 to 6 carbon atoms, and R4 is alkyl having 1 to 6 carbon atoms or amino group.
摘要:
A curing agent for epoxy resins, the curing agent containing as an active ingredient a compound represented by the formula (1) or a salt thereof and an amine compound or a salt thereof, the curing agent being characterized in that at least one of the compound represented by the formula (1) and the amine compound is a salt of thiocyanic acid; and an epoxy resin composition having the curing agent incorporated therein: NH2N(R1)(R2) (1) wherein R1 and R2 are the same or different and each represents alkyl having 1 to 8 carbon atoms, aryl, a nitrogen-containing heterocyclic group or when taken together, represents alkylene having 2 to 11 carbon atoms or a group represented by —R3—R4—R5— wherein R3 and R5 are the same or different and each represents alkylene having 1 to 8 carbon atoms, and R4 is an oxygen atom, a sulfur atom or a group ═NR6 or ═NNH2, wherein R6 is a hydrogen atom or alkyl having 1 to 8 carbon atoms.
摘要:
It is an object of the present invention to retain on an artificial blood vessel material an endothelial cell growth-promoting agent, for example the angiogenic factor HGF, without impairing its activity, thereby providing an artificial blood vessel having the function of promoting endothelialization. Such an object can be attained by an artificial blood vessel that includes a porous tubular structure formed from, for example, polytetrafluoroethylene and, layered and immobilized in sequence onto at least the inner surface thereof, (1) a polyamino acid urethane copolymer, (2) collagen or gelatin, and (3) an endothelial cell growth-promoting agent having collagen-binding activity. Preferred examples of the endothelial cell growth-promoting agent include a fusion protein of a polypeptide having collagen-binding activity such as, for example, a fibronectin-derived polypeptide and an angiogenic factor, in particular, HGF.
摘要:
Provided is a peptide including the following amino acid sequence. Tyr-Xaa0-Xaa1-Tyr-Tyr-Xaa2-Xaa3-Tyr-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11 (SEQ ID NO: 4: wherein Xaa0, Xaa1, Xaa2, Xaa3, Xaa4, Xaa5, Xaa6, Xaa7, Xaa8, Xaa9, Xaa10 and Xaa 11 represent any amino acid) or Tyr-Asn-Asp-Tyr-Tyr-Tyr-Tyr-Cys-Tyr-Arg-Asp-Tyr-Asp (SEQ ID NO: 20).
摘要翻译:提供了包含以下氨基酸序列的肽。 Tyr-Xaa0-Xaa1-Tyr-Tyr-Xaa2-Xaa3-Tyr-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11(SEQ ID NO:4:其中Xaa0,Xaa1,Xaa2,Xaa3,Xaa4,Xaa5 ,Xaa6,Xaa7,Xaa8,Xaa9,Xaa10和Xaa11表示任何氨基酸)或Tyr-Asn-Asp-Tyr-Tyr-Tyr-Tyr-Cys-Tyr-Arg-Asp-Tyr-Asp(SEQ ID NO: )。
摘要:
Provision of a trimeric chimera protein which has sufficiently retained physiological activity of a physiologically active peptide simultaneously with fibril-forming ability of a collagen. A trimeric chimera protein comprising a collagen and a biologically active peptide fused to the collagen, wherein the biologically active peptide is fused on the side of the amino terminal of the collagen, and the collagen is a fibril-forming collagen having a triple helical structure in its triple helix region.
摘要:
Hydrazine supply device (1) includes hydrazine fixing bath (2) which releasably fixes hydrazine and water/alkali, tank (3) for supplying water or an alkaline aqueous solution so as to release the hydrazine fixed in the hydrazine fixing bath (2), thereby achieving stable storage and supply of hydrazine. Thus, the device can be widely used in various industrial fields requiring the supply of hydrazine. Further, each of fuel cell system (10) and vehicle (14) comprises the hydrazine supply device (1) and fuel cell (13), thereby achieving safe utilization of hydrazine as fuel and reduction of burdens on the environmental load.
摘要:
A hydrazine-fixing group such as a ketone group, a formyl group, a chlormethyl group or an amide group, which is capable of releasably fixing hydrazine, is introduced into a side chain of a synthetic resin, and hydrazine is fixed to the hydrazine-fixing group. Since a hydrazine storage resin of the present invention has a hydrazine-releasable group capable of releasing hydrazine, it is able to store hydrazine stably. In addition, hydrazine can be supplied by releasing hydrazine from the hydrazine-releasable group. Consequently, the hydrazine storage resin can be widely used in various industrial fields requiring supply of hydrazine.
摘要:
The present invention relates to a hemorrhage reducing agent in cerebrovascular disorder containing a poly (ADP-ribose) polymerase inhibitor (PARP inhibitor). The PARP inhibitor provides an inhibitory effect of vascular endothelial cell disorder so that it may reduce hemorrhage in cerebrovascular disorder. In addition, the PARP inhibitor inhibits the hemorrhage that is concerned about in thrombolytic agent use by using together with a thrombolytic agent, and an effect of extending therapeutic time window of a thrombolytic agent may be further expected. Furthermore, the PARP inhibitor can be a safe hemorrhage reducing agent with fewer side effects because it does not affect the blood coagulation system and the fibrinolytic system.